WO2010066569A1 - Modulation of infant fat mass - Google Patents

Modulation of infant fat mass Download PDF

Info

Publication number
WO2010066569A1
WO2010066569A1 PCT/EP2009/065662 EP2009065662W WO2010066569A1 WO 2010066569 A1 WO2010066569 A1 WO 2010066569A1 EP 2009065662 W EP2009065662 W EP 2009065662W WO 2010066569 A1 WO2010066569 A1 WO 2010066569A1
Authority
WO
WIPO (PCT)
Prior art keywords
infant
composition
during
protein
period
Prior art date
Application number
PCT/EP2009/065662
Other languages
French (fr)
Inventor
Marie-Claire Fichot
Catherine Mace
Philippe Steenhout
Original Assignee
Nestec S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec S.A. filed Critical Nestec S.A.
Priority to MX2011004921A priority Critical patent/MX2011004921A/en
Priority to RU2011128029/13A priority patent/RU2540541C2/en
Priority to CN2009801466665A priority patent/CN102223812A/en
Priority to BRPI0922247-2A priority patent/BRPI0922247A2/en
Priority to US13/133,295 priority patent/US9462821B2/en
Priority to CA2745246A priority patent/CA2745246A1/en
Priority to EP09756317A priority patent/EP2373183A1/en
Priority to AU2009326395A priority patent/AU2009326395B2/en
Publication of WO2010066569A1 publication Critical patent/WO2010066569A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to the modulation of infant fat mass.
  • Dietary protein provides the essential amino acids necessary for protein synthesis and growth and, in infant formula, both protein quality and protein quantity are important. Infant formulas are usually based on cows' milk but the amino acid profile of cows' milk is noticeably different from that of human milk. In the past, in order to supply enough of the essential amino acids, infant formulas based on cows' milk had to have a protein content significantly higher than that of the human milk, which, in fact, has the lowest protein concentration found in any mammal ranging from 1.4 to 1.8 g per 100 kcal for mature human milk. Over the past 5 to 10 years, this has led to a tendency to decrease the protein content in infant formulas. For example, in EP 1220620, an infant formula composition is proposed in which the protein amounts to between 9.0 and 10.0% on a weight for weight basis. This corresponds to about 1.8g protein/ 100 kcal which is comparable to the level of protein in mature human milk.
  • the protein content of infant formulas is between 1.8 and 3.5 g/100 kcal with the protein content of starter formulas being towards the lower end of the range and the protein content of follow-on formulas being toward the upper end of the range.
  • the protein content of Nestle NAN 1 ® starter infant formula is 1.83g/100 kcal and the protein content of Nestle NAN 2 ® follow-on infant formula is 3.1g/100 kcal.
  • Certain benefits have been shown to be associated with feeding starter infant formulas with about 1.8g protein/100 kcal to infants during the first few months of life.
  • the evolution of plasma IGF-I levels in infants fed with an infant formula containing 1.83g protein/100 kcal was closer to that of breast fed infants over the first few months of life than was that of infants fed an infant formula containing 2.39g protein/100 kcal.
  • feeding an infant formula with a relatively high protein content during the neonatal period may reduce fat mass accumulated during the neonatal period (compared to fat mass accumulated by infants fed an infant formula with a lower protein content during the same period).
  • the present invention provides the use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the accumulation of fat mass in the neonatal period wherein the composition contains at least 2.4g of protein per lOOkcal.
  • the invention also extends to the use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the risk of development of obesity later in life wherein the composition contains at least 2.4g of protein per lOOkcal.
  • the invention further extends to a method of reducing the accumulation of fat mass in a neonatal human infant at risk thereof which method comprises administering to the infant during at least a part of the neonatal period a therapeutic amount of a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4g of protein per lOOkcal.
  • the invention also extends to a method of reducing the possibility that an infant will develop obesity later in life comprising feeding to the infant during at least a part of the neonatal period a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4g of protein per lOOkcal.
  • Weight gain during the first week of life has been associated with overweight in adulthood (Stettler N, Stallings VA, Troxel AB, Zhao J, Schinnar R, Nelson SE, Ziegler EE, Strom BL. Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005). 111 :1897-903). It therefore follows that a nutritional intervention which reduces accumulation of fat mass in the neonatal period - or, in other words, results in an accumulation of fat mass during the neonatal period which mimics that of a breast fed infant - may reduce the risk of overweight and obesity later in life.
  • Neonatal infant means an infant in the first month of life
  • Neonatal period means the first month of life.
  • references to the energy density of the nutritional composition in a specified number of kilocalories per litre refer, in the context of powdered products, to the product after re-constitution according to the directions provided with the product.
  • the nutritional composition for use in the present invention contains between 2.4 and 3.Og protein/1 OOkcal, more preferably between 2.4 and 2.8 g/100kcal.
  • the nutritional composition containing more than 2.4g of protein/ 1 OOkcal is fed to the infant for at least the first two weeks of life.
  • feeding with the said composition may continue for the whole of the neonatal period whereafter the infant may be fed with a nutritional composition containing from 1.7 to 2.Og protein/ 100 kcal.
  • the source of the protein is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
  • protein sources based on cows' milk proteins such as whey, casein and mixtures thereof may be used as well as protein sources based on soy.
  • the protein source may be based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include alpha- lactalbumin and beta-lactoglobulin in whatever proportions are desired.
  • the protein source is based on modified sweet whey.
  • Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of infant formulas based on cows' milk.
  • sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino-glyco-macropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk.
  • This modified sweet whey can then be supplemented with those amino acids in respect of which it has a low content (principally histidine, arginine and tryptophan).
  • modified sweet whey A process for removing CGMP from sweet whey is described in EP 880902 and an infant formula based on this modified sweet whey is described in WO 01/11990.
  • modified sweet whey it is may be supplemented by free arginine in an amount of from 0.1 to 3% by weight and/or free histidine in an amount of from 0.1 to 1.5% by weight.
  • the proteins may be intact or hydrolysed or a mixture of intact and hydro lysed proteins although intact proteins are generally preferred.
  • the protein source may be hydrolysed as desired and as is known in the art.
  • a whey protein hydro lysate may be prepared by enzymatically hydro lysing the whey fraction in two steps as disclosed in EP 322589. If the whey fraction used as the starting material is substantially lactose free, it is found that the protein suffers much less lysine blockage during the hydrolysis process. This enables the extent of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example about 7% by weight of lysine which greatly improves the nutritional quality of the protein source.
  • the nutritional composition for use in the present invention is an infant formula.
  • a nutritionally complete composition will also contain other ingredients of the type conventionally found in infant formulas such as carbohydrates, fats, vitamins and minerals as well as semi-essential nutrients.
  • carbohydrate sources contribute between 35 and 65% of the total energy of the formula
  • the lipid source may be any lipid or fat which is suitable for use in infant formulas.
  • Preferred fat sources include palm olein, high oleic sunflower oil and high oleic safflower oil.
  • the essential fatty acids linoleic and ⁇ -linolenic acid may also be added as may small amounts of oils containing high quantities of preformed arachidonic acid and docosahexaenoic acid such as fish oils or microbial oils.
  • the fat content is preferably such as to contribute between 30 to 55% of the total energy of the formula.
  • the fat source preferably has a ratio of n-6 to n-3 fatty acids of about 5:1 to about 15:1; for example about 8:1 to about 10:1.
  • the infant formula will also contain all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the infant formula include vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin Bi 2 , vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form. The presence and amounts of specific minerals and other vitamins will vary depending on the intended infant population.
  • the infant formula may contain emulsifiers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the formula is provided in liquid form.
  • the infant formula may optionally contain other substances which may have a beneficial effect such as fibres, lactoferrin, nucleotides, nucleosides, and the like.
  • Probiotic bacteria such as Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Bifidobacterium lactis CNCM 1-3446, Bifidobacterium longum ATCC BAA-999, the strain of Bifidobacterium breve sold by Danisco under the trade mark Bb-03, the strain of Bifidobacterium breve sold by Morinaga under the trade mark M- 16V, the strain of Bifidobacterium breve sold by Institut Rosell (Lallemand) under the trade mark R0070 and the strain of Bifidobacterium infantis sold by Procter & Gamble Co.
  • the infant formula may be prepared in any suitable manner.
  • an infant formula may be prepared by blending together the protein source, the carbohydrate source, and the fat source in appropriate proportions.
  • emulsifiers may be included in the blend at this stage.
  • the vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending.
  • Water preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
  • the liquid mixture may then be thermally treated to reduce bacterial loads.
  • the liquid mixture may be rapidly heated to a temperature in the range of about 80 0 C to about 110 0 C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
  • the liquid mixture may then be cooled to about 60 0 C to about 85°C; for example by flash cooling.
  • the liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage.
  • the homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added.
  • the pH and solids content of the homogenised mixture is conveniently standardised at this point.
  • the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • the powder should have a moisture content of less than about 5% by weight.
  • the homogenised mixture is filled into suitable containers; preferably aseptically.
  • the liquid infant formula may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available.
  • the liquid infant formula may be in the form of a ready to feed formula having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
  • DHA (docosahexaenoic acid) is used as part of the composition of the invention, especially during perinatal period.
  • This may include both the supplementation of the pregnant mothers with DHA and/or the administration of DHA to the young infants during the perinatal period (preferably between birth and 6 months of age, between birth and 3 months of age, between birth and 4 weeks of age, or between birth and 1 week of age). It has been evidenced (see example 3) that such administration of DHA has a positive effect on the fat mass of the infants after birth.
  • the invention comprises both the use and administration of the above described proteinic features and the administration of DHA.
  • the DHA (docosahexaenoic acid) is administered to the infant.
  • the DHA (docosahexaenoic acid) is administered to the mother during the gestation period, preferably during the last ⁇ months, last 3 months, last 4 weeks, or last week of the gestation period. . In one embodiment the DHA is administered to both the mother during the gestation period (preferably according to the regimen above) and to the infant after birth (preferably according to the regimen above).
  • he DHA is comprised in the diet at a level of between 0.1% and 4%, preferably between 0.3% and 2.5%, most preferably between 0.5 and 1%, In one embodiment the supplementation is at 0.75% DHASCO oil (corresponding to 2.4% DHA of total fatty acids).
  • the invention comprises a composition according as described above for administration to infants during perinatal period, for obtaining a low fat body mass accumulation during the neonatal period.
  • the invention comprises a kit of part comprising a composition to be administered to the infant as described above and also comprising a composition for administration to pregnant female, preferably during the last ⁇ months, last 3 months or last 4 weeks of the gestational period, for helping obtaining a low fat body mass accumulation in the infant during the neonatal period.
  • the low body mass accumulation is cited in comparison to the average fat body mass accumulation obtained in infants receiving a regular diet.
  • composition of a suitable infant formula to be used in the present invention is given below:
  • This example demonstrates the effect of the protein content of an infant formula used as the sole source of nutrition for a group of infants for the first month of their life on their body composition.
  • the two formulas were isocaloric having an energy density of 670 kcal/litre. In both cases, the wheyxasein ration was 70:30.
  • the formulas were supplied packed in metal cans with their identity marked by a letter coding known only to the investigating staff. The duration of the study was 12 months.
  • infants 125 boys and 113 girls were recruited, 74 to the Fl.8 group, 80 to the F2.7 group and 84 to the reference group.
  • the infants were fed their assigned formula or breast milk ad libitum as the sole source of nutrition.
  • Body composition (BC) measurements were used to assess fat mass (FM) gain during the first year of age using PEA-POD methodology.
  • PEA-POD is designed to measure the BC of babies from birth to 6 months using principles similar to hydrostatic weighing (underwater weighing). Instead of using water to measure body volume, PEA-POD uses air displacement plethysmography as a densitometric technique in which body fat is assessed from direct measurement of subject mass volume to measure body volume.
  • the calorie intake did not differ between the formula groups and growth parameters including gain of body weight, head circumference and length were identical between the 3 groups.
  • the accumulated fat mass was not different between the formula- fed groups but was significantly higher in the Fl.8 group compared to the reference group (fat mass: 13.2 ⁇ 3.4 vs 11.8 ⁇ 3.5%, p ⁇ 0.01;).
  • the F2.7 group showed no significant difference of fat mass (12.7 ⁇ 3.4%) when compared to the reference group (see figure 1).
  • Maternal and perinatal DHA supplementation reduces fat mass in the neonate guinea pig
  • DHA docosahexaenoic acid
  • DHASCO oil corresponding to 2.4% DHA of total fatty acids; DHA is available from Martek Biosciences, Columbia, MD, USA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of reducing the accumulation of fat mass in a neonatal human infant at risk thereof which method comprises administering to the infant during at least a part of the neonatal period a therapeutic amount of a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4g of protein per 100kcal. As weight gain during the first week of life has been associated with overweight in adulthood, this may offer a method of reducing the risk of developing obesity in later life. Also claimed is the administration of DHA to the mother during gestation period.

Description

Modulation of Infant Fat Mass
This invention relates to the modulation of infant fat mass.
Mother's milk is recommended for all infants. However, in some cases breast feeding is inadequate or unsuccessful or inadvisable for medical reasons or the mother chooses not to breast feed. Infant formulas have been developed for these situations. Greater knowledge of the composition of human milk affords the opportunity to design infant formulas that are closer in composition to human milk. Particular consideration has been given to devising formulas consumption of which results in growth and metabolic patterns similar to those of breastfed infants, in the hope that this will result in the development of similar health characteristics in later childhood and adulthood.
Conventional infant formulas fall into two categories, starter formulas for infants from the age of birth to 4 to 6 months and which provide complete nutrition for this age group and so-called follow-on formulas for infants between the ages of four to six months and twelve months which are fed to the infants in combination with increasing amounts of other foods such as infant cereals and pureed fruits, vegetables and other foodstuffs as the process of weaning progresses.
Dietary protein provides the essential amino acids necessary for protein synthesis and growth and, in infant formula, both protein quality and protein quantity are important. Infant formulas are usually based on cows' milk but the amino acid profile of cows' milk is noticeably different from that of human milk. In the past, in order to supply enough of the essential amino acids, infant formulas based on cows' milk had to have a protein content significantly higher than that of the human milk, which, in fact, has the lowest protein concentration found in any mammal ranging from 1.4 to 1.8 g per 100 kcal for mature human milk. Over the past 5 to 10 years, this has led to a tendency to decrease the protein content in infant formulas. For example, in EP 1220620, an infant formula composition is proposed in which the protein amounts to between 9.0 and 10.0% on a weight for weight basis. This corresponds to about 1.8g protein/ 100 kcal which is comparable to the level of protein in mature human milk.
Typically, the protein content of infant formulas is between 1.8 and 3.5 g/100 kcal with the protein content of starter formulas being towards the lower end of the range and the protein content of follow-on formulas being toward the upper end of the range. For example, the protein content of Nestle NAN 1 ® starter infant formula is 1.83g/100 kcal and the protein content of Nestle NAN 2 ® follow-on infant formula is 3.1g/100 kcal.
Certain benefits have been shown to be associated with feeding starter infant formulas with about 1.8g protein/100 kcal to infants during the first few months of life. For example, according to WO2006/069918, the evolution of plasma IGF-I levels in infants fed with an infant formula containing 1.83g protein/100 kcal was closer to that of breast fed infants over the first few months of life than was that of infants fed an infant formula containing 2.39g protein/100 kcal.
It has been demonstrated in infant monkeys that reducing the protein content of the formula results in a growth pattern and early age insulin and glucose metabolism more similar to that of a control breast fed group than to those of groups fed formula with higher protein contents. The implication is that increased IGF-I levels may result in a different body composition and an increased predisposition to obesity in later life. Childhood overweight and obesity currently affects 18 million children under age 5 worldwide. Almost 30% of US children and adolescents and between 10 and 30% of European children are overweight or obese.
There is, therefore, clearly a need for further investigation into the impact of early nutrition on body composition in infancy and on the risk of developing obesity later in life.
Summary of the Invention
It has now surprisingly been found that feeding an infant formula with a relatively high protein content during the neonatal period may reduce fat mass accumulated during the neonatal period (compared to fat mass accumulated by infants fed an infant formula with a lower protein content during the same period).
Accordingly, the present invention provides the use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the accumulation of fat mass in the neonatal period wherein the composition contains at least 2.4g of protein per lOOkcal.
The invention also extends to the use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the risk of development of obesity later in life wherein the composition contains at least 2.4g of protein per lOOkcal.
The invention further extends to a method of reducing the accumulation of fat mass in a neonatal human infant at risk thereof which method comprises administering to the infant during at least a part of the neonatal period a therapeutic amount of a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4g of protein per lOOkcal.
The invention also extends to a method of reducing the possibility that an infant will develop obesity later in life comprising feeding to the infant during at least a part of the neonatal period a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4g of protein per lOOkcal.
Weight gain during the first week of life has been associated with overweight in adulthood (Stettler N, Stallings VA, Troxel AB, Zhao J, Schinnar R, Nelson SE, Ziegler EE, Strom BL. Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005). 111 :1897-903). It therefore follows that a nutritional intervention which reduces accumulation of fat mass in the neonatal period - or, in other words, results in an accumulation of fat mass during the neonatal period which mimics that of a breast fed infant - may reduce the risk of overweight and obesity later in life.
Detailed Description of the Invention
In this specification, the following expressions have the following meanings :-
"Infant" means a child under the age of 12 months;
"Neonatal infant" means an infant in the first month of life;
"Neonatal period" means the first month of life.
All percentages and ratios are by weight unless otherwise specified.
References to the energy density of the nutritional composition in a specified number of kilocalories per litre refer, in the context of powdered products, to the product after re-constitution according to the directions provided with the product. Preferably the nutritional composition for use in the present invention contains between 2.4 and 3.Og protein/1 OOkcal, more preferably between 2.4 and 2.8 g/100kcal.
Preferably the nutritional composition containing more than 2.4g of protein/ 1 OOkcal is fed to the infant for at least the first two weeks of life. Optionally feeding with the said composition may continue for the whole of the neonatal period whereafter the infant may be fed with a nutritional composition containing from 1.7 to 2.Og protein/ 100 kcal.
The source of the protein is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured. Thus, protein sources based on cows' milk proteins such as whey, casein and mixtures thereof may be used as well as protein sources based on soy. As far as whey proteins are concerned, the protein source may be based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include alpha- lactalbumin and beta-lactoglobulin in whatever proportions are desired.
Preferably, however, the protein source is based on modified sweet whey. Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of infant formulas based on cows' milk. However, sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino-glyco-macropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk. This modified sweet whey can then be supplemented with those amino acids in respect of which it has a low content (principally histidine, arginine and tryptophan). A process for removing CGMP from sweet whey is described in EP 880902 and an infant formula based on this modified sweet whey is described in WO 01/11990. Such protein sources have been shown in animal and human studies to have a protein efficiency ratio, nitrogen digestibility, biological value and net protein utilisation comparable to standard whey-adapted protein sources with a much higher protein content per 100 kcal and to result in satisfactory growth. If modified sweet whey is used as the protein source, it is may be supplemented by free arginine in an amount of from 0.1 to 3% by weight and/or free histidine in an amount of from 0.1 to 1.5% by weight. The proteins may be intact or hydrolysed or a mixture of intact and hydro lysed proteins although intact proteins are generally preferred. However, it may be desirable to supply partially hydrolysed proteins (degree of hydrolysis between 2 and 20%), for example for infants believed to be at risk of developing cows' milk allergy. If hydrolysed proteins are required, the protein source may be hydrolysed as desired and as is known in the art. For example, a whey protein hydro lysate may be prepared by enzymatically hydro lysing the whey fraction in two steps as disclosed in EP 322589. If the whey fraction used as the starting material is substantially lactose free, it is found that the protein suffers much less lysine blockage during the hydrolysis process. This enables the extent of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example about 7% by weight of lysine which greatly improves the nutritional quality of the protein source.
Preferably the nutritional composition for use in the present invention is an infant formula. Such a nutritionally complete composition will also contain other ingredients of the type conventionally found in infant formulas such as carbohydrates, fats, vitamins and minerals as well as semi-essential nutrients.
The preferred source of carbohydrates is lactose although other carbohydrates such as saccharose, maltodextrin, and starch may also be added. Preferably carbohydrate sources contribute between 35 and 65% of the total energy of the formula
The lipid source may be any lipid or fat which is suitable for use in infant formulas. Preferred fat sources include palm olein, high oleic sunflower oil and high oleic safflower oil. The essential fatty acids linoleic and α-linolenic acid may also be added as may small amounts of oils containing high quantities of preformed arachidonic acid and docosahexaenoic acid such as fish oils or microbial oils. In total, the fat content is preferably such as to contribute between 30 to 55% of the total energy of the formula. The fat source preferably has a ratio of n-6 to n-3 fatty acids of about 5:1 to about 15:1; for example about 8:1 to about 10:1.
The infant formula will also contain all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the infant formula include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin Bi2, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form. The presence and amounts of specific minerals and other vitamins will vary depending on the intended infant population.
If necessary, the infant formula may contain emulsifiers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the formula is provided in liquid form.
The infant formula may optionally contain other substances which may have a beneficial effect such as fibres, lactoferrin, nucleotides, nucleosides, and the like. Probiotic bacteria such as Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Bifidobacterium lactis CNCM 1-3446, Bifidobacterium longum ATCC BAA-999, the strain of Bifidobacterium breve sold by Danisco under the trade mark Bb-03, the strain of Bifidobacterium breve sold by Morinaga under the trade mark M- 16V, the strain of Bifidobacterium breve sold by Institut Rosell (Lallemand) under the trade mark R0070 and the strain of Bifidobacterium infantis sold by Procter & Gamble Co. under the trade mark Bifantis may also be included
The infant formula may be prepared in any suitable manner. For example, an infant formula may be prepared by blending together the protein source, the carbohydrate source, and the fat source in appropriate proportions. If used, emulsifiers may be included in the blend at this stage. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
The liquid mixture may then be thermally treated to reduce bacterial loads. For example, the liquid mixture may be rapidly heated to a temperature in the range of about 800C to about 1100C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
The liquid mixture may then be cooled to about 600C to about 85°C; for example by flash cooling. The liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage. The homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added. The pH and solids content of the homogenised mixture is conveniently standardised at this point.
If it is desired to produce a powdered infant formula, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder. The powder should have a moisture content of less than about 5% by weight.
If it is desired to produce a liquid infant formula, the homogenised mixture is filled into suitable containers; preferably aseptically. However, the liquid infant formula may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available. The liquid infant formula may be in the form of a ready to feed formula having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
In one embodiment of the invention, DHA (docosahexaenoic acid) is used as part of the composition of the invention, especially during perinatal period. This may include both the supplementation of the pregnant mothers with DHA and/or the administration of DHA to the young infants during the perinatal period (preferably between birth and 6 months of age, between birth and 3 months of age, between birth and 4 weeks of age, or between birth and 1 week of age). It has been evidenced (see example 3) that such administration of DHA has a positive effect on the fat mass of the infants after birth. In one embodiment the invention comprises both the use and administration of the above described proteinic features and the administration of DHA. In one embodiment the DHA (docosahexaenoic acid) is administered to the infant. In one embodiment the DHA (docosahexaenoic acid) is administered to the mother during the gestation period, preferably during the last βmonths, last 3 months, last 4 weeks, or last week of the gestation period. . In one embodiment the DHA is administered to both the mother during the gestation period (preferably according to the regimen above) and to the infant after birth (preferably according to the regimen above).
In one embodiment he DHA is comprised in the diet at a level of between 0.1% and 4%, preferably between 0.3% and 2.5%, most preferably between 0.5 and 1%, In one embodiment the supplementation is at 0.75% DHASCO oil (corresponding to 2.4% DHA of total fatty acids).
In one embodiment the invention comprises a composition according as described above for administration to infants during perinatal period, for obtaining a low fat body mass accumulation during the neonatal period.
In one embodiment the invention comprises a kit of part comprising a composition to be administered to the infant as described above and also comprising a composition for administration to pregnant female, preferably during the last βmonths, last 3 months or last 4 weeks of the gestational period, for helping obtaining a low fat body mass accumulation in the infant during the neonatal period.
In one embodiment the low body mass accumulation is cited in comparison to the average fat body mass accumulation obtained in infants receiving a regular diet.
The invention will now be further illustrated by reference to the following examples.
Example 1
An example of the composition of a suitable infant formula to be used in the present invention is given below:-
Figure imgf000010_0001
The following example is given by way of illustration only and should not be construed as limiting the subject-matter of the present application.
Example 2
Effect of the level of dietary protein in the neonatal period on infant body composition
This example demonstrates the effect of the protein content of an infant formula used as the sole source of nutrition for a group of infants for the first month of their life on their body composition.
A randomized, controlled, double-blinded study of three groups in parallel (being two experimental groups each of which was fed a different infant formula as described in more detail below and a third group of wholly breast-fed infants as a reference) and was carried out at the Reanimation Neonatale et Neonatologie, Hόpital de Ia Croix Rousse, Lyon, France in accordance with the principles established in the 1964 Declaration of Helsinki ( as amended) and with the approval of the CCPPRB Lyon A.
Only healthy newborn infants with healthy mothers having a normal BMI before pregnancy and not having diabetes were considered for inclusion. Infants meeting these criteria whose mothers had decided not to breast feed at all for the first four months of the life of their infant were randomly assigned to one of the two experimental groups. Infants whose mothers had decided to breast feed exclusively for the first three months of the life of their infant were assigned to the reference group.
Of the experimental groups, one was fed the formula with 2.7g protein/ lOOkcal (F2.7 group) and the other was fed a formula with 1.83g protein/100 kcal (Fl.8 group). Detailed compositions of the formulas are given in the table below.
Figure imgf000012_0001
Figure imgf000013_0001
The two formulas were isocaloric having an energy density of 670 kcal/litre. In both cases, the wheyxasein ration was 70:30. The formulas were supplied packed in metal cans with their identity marked by a letter coding known only to the investigating staff. The duration of the study was 12 months.
238 infants (125 boys and 113 girls) were recruited, 74 to the Fl.8 group, 80 to the F2.7 group and 84 to the reference group. The infants were fed their assigned formula or breast milk ad libitum as the sole source of nutrition.
Growth parameters and body composition were determined at the age of 2 weeks ± 2 days. Body composition (BC) measurements were used to assess fat mass (FM) gain during the first year of age using PEA-POD methodology. PEA-POD is designed to measure the BC of babies from birth to 6 months using principles similar to hydrostatic weighing (underwater weighing). Instead of using water to measure body volume, PEA-POD uses air displacement plethysmography as a densitometric technique in which body fat is assessed from direct measurement of subject mass volume to measure body volume.
The calorie intake did not differ between the formula groups and growth parameters including gain of body weight, head circumference and length were identical between the 3 groups. As shown in Figure 1, at 2 weeks of age, the accumulated fat mass was not different between the formula- fed groups but was significantly higher in the Fl.8 group compared to the reference group (fat mass: 13.2 ± 3.4 vs 11.8 ± 3.5%, p<0.01;). The F2.7 group showed no significant difference of fat mass (12.7 ± 3.4%) when compared to the reference group (see figure 1).
These results show that protein intake during the first 2 weeks of life does not impact growth parameters. However, a low protein intake leads to an increased adiposity when compared to breastfeeding.
Example 3
Maternal and perinatal DHA supplementation reduces fat mass in the neonate guinea pig
In one embodiment of the invention, the effect of DHA (docosahexaenoic acid) was investigated. The effects of maternal docosahexaenoic acid (DHA) supplementation on body weight and fat mass development in the neonate guinea pig were studied. Female guinea pigs were fed a diet supplemented or not with 0.75% DHASCO oil (corresponding to 2.4% DHA of total fatty acids; DHA is available from Martek Biosciences, Columbia, MD, USA) during pregnancy and lactation. The fatty acid analysis of the dam's milk, collected 3 days after delivery, showed detectable levels of DHA (1.8% of total fatty acids) only in the supplemented group. At 2 days of age, the body weight of the offspring was identical in both groups (Figure 2) while the % of fat mass was significantly lower in the DHA supplemented group (-DHA: 16.0 ± 0.6%; +DHA: 12.7 ± 0.4%, p<0.001) (Figure 4). At day 21, this difference in % fat mass between groups was attenuated but still significant (Figure 3). These results show that perinatal DHA intake reduces fat accretion during fetal life and/or the first postnatal days. Further studies will be needed for understanding the mechanism of action of DHA on adipose tissue development in early life and the consequences later on.

Claims

Claims
1. The use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the accumulation of fat mass in the neonatal period wherein the composition contains at least 2.4g of protein per lOOkcal.
2. The use of a source of proteins for the preparation of nutritional composition for administration to a human infant during at least a part of the neonatal period so as to reduce the risk of development of obesity later in life wherein the composition contains at least 2.4g of protein per lOOkcal.
3. The use of Claim 1 or 2, wherein the composition comprises between 2.4 and 3.O g of protein per lOOkcal.
4. The use of any preceding claim wherein the composition comprises between 2.4 and 2.8 g of protein per lOOkcal.
5. The use of any preceding claim, wherein the nutritional composition is administered to the infant for the whole of the neonatal period.
6. The use of any preceding claim, wherein the proteins are intact.
7. The use of any of Claims 1 to 5, wherein the proteins are partially hydrolysed.
8. The use of Claim 7 wherein the degree of hydrolysis of the proteins is between 2 and 20%.
9. The use of any preceding claim, wherein the nutritional composition is an infant formula.
10. The use of any preceding claim wherein administration of the nutritional composition having a protein content of at least 2.4g per lOOkcal is followed by administration of a nutritional composition having a protein content between 1.7 and 2.Og protein per 100 kcal for the remainder of the first four months of the life of the infant.
11. The use of any of the preceding claims wherein DHA (docosahexaenoic acid) is administered to the infant as part of said composition.
12. The use of any of the preceding claims wherein the DHA (docosahexaenoic acid) is administered to the mother during the gestation period, preferably during the last 3 months of the gestation period.
13. A composition according to any of the preceding claim for administration to infants during perinatal period, for obtaining a low fat body mass accumulation during the neonatal period.
14. A kit of part comprising the composition of claim 13 or of any of the preceding claims, said kit also comprising a composition for administration to pregnant female, preferably during the last 3 months of the gestational period, for helping obtaining a low fat body mass accumulation in the infant during the neonatal period.
PCT/EP2009/065662 2008-12-08 2009-11-23 Modulation of infant fat mass WO2010066569A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2011004921A MX2011004921A (en) 2008-12-08 2009-11-23 Modulation of infant fat mass.
RU2011128029/13A RU2540541C2 (en) 2008-12-08 2009-11-23 Reduction of body fat weight with infant
CN2009801466665A CN102223812A (en) 2008-12-08 2009-11-23 Modulation of infant fat mass
BRPI0922247-2A BRPI0922247A2 (en) 2008-12-08 2009-11-23 Fat mass modulation in lactating women.
US13/133,295 US9462821B2 (en) 2008-12-08 2009-11-23 Modulation of infant fat mass
CA2745246A CA2745246A1 (en) 2008-12-08 2009-11-23 Modulation of infant fat mass
EP09756317A EP2373183A1 (en) 2008-12-08 2009-11-23 Modulation of infant fat mass
AU2009326395A AU2009326395B2 (en) 2008-12-08 2009-11-23 Modulation of infant fat mass

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170936 2008-12-08
EP08170936.2 2008-12-08

Publications (1)

Publication Number Publication Date
WO2010066569A1 true WO2010066569A1 (en) 2010-06-17

Family

ID=40688400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065662 WO2010066569A1 (en) 2008-12-08 2009-11-23 Modulation of infant fat mass

Country Status (10)

Country Link
US (1) US9462821B2 (en)
EP (1) EP2373183A1 (en)
CN (1) CN102223812A (en)
AU (1) AU2009326395B2 (en)
BR (1) BRPI0922247A2 (en)
CA (1) CA2745246A1 (en)
MX (1) MX2011004921A (en)
RU (1) RU2540541C2 (en)
TW (1) TW201026232A (en)
WO (1) WO2010066569A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
EP2614725A1 (en) * 2012-01-13 2013-07-17 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for improving lean body mass development and formation and reducing adverse health effects later in life in offspring
EP2614724A1 (en) * 2012-01-13 2013-07-17 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring
WO2013106663A1 (en) * 2012-01-13 2013-07-18 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for effecting the offspring
EP3073844B1 (en) 2013-11-29 2020-01-22 Société des Produits Nestlé S.A. Age-tailored nutritional compositions with a varying protein content
US10729733B2 (en) 2013-05-10 2020-08-04 H.J. Heinz Company Brands Llc Probiotics and methods of use
EP3442358B1 (en) 2016-04-11 2021-02-17 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085549A1 (en) * 2013-12-12 2015-06-18 Nestec S.A. An age-tailored nutrition system for an infant
CN106659227B (en) 2014-05-19 2022-02-11 N·V·努特里奇亚 Formulations comprising optimized amino acid profiles
US20160155347A1 (en) * 2014-11-27 2016-06-02 Nestec S.A. Devices, systems and methods of assessing the foundations for the healthy development of an infant or a young child
CN104839718A (en) * 2015-05-26 2015-08-19 南阳市汇博生物技术有限公司 Powder-form full-nutrient formula food and production process thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007004878A2 (en) * 2005-07-01 2007-01-11 N.V. Nutricia Infant nutrition with hydrolised proteins
US20070026049A1 (en) * 2003-12-19 2007-02-01 Nancy Auestad Method of increasing lean body mass and reducing body fat mass in infants
WO2007135141A1 (en) * 2006-05-23 2007-11-29 Nestec S.A. Maternal supplement
EP1932437A1 (en) * 2006-12-15 2008-06-18 Nestec S.A. Infant formula

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162472A (en) * 1998-07-28 2000-12-19 University Of Virginia Patent Foundation Nutritional formula for premature infants and method of making
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
PL1962823T3 (en) * 2005-12-23 2015-08-31 Nutricia Nv Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026049A1 (en) * 2003-12-19 2007-02-01 Nancy Auestad Method of increasing lean body mass and reducing body fat mass in infants
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007004878A2 (en) * 2005-07-01 2007-01-11 N.V. Nutricia Infant nutrition with hydrolised proteins
WO2007135141A1 (en) * 2006-05-23 2007-11-29 Nestec S.A. Maternal supplement
EP1932437A1 (en) * 2006-12-15 2008-06-18 Nestec S.A. Infant formula

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERGMANN RENATE LUCIA ET AL: "Does maternal docosahexaenoic acid supplementation during pregnancy and lactation lower BMI in late infancy?", JOURNAL OF PERINATAL MEDICINE, vol. 35, no. 4, 2007, pages 295 - 300, XP009132020, ISSN: 0300-5577 *
COURVILLE AMBER B ET AL: "DHA-functional food in pregnancy decreases infant ponderal index and cord blood insulin concentration", April 2007, FASEB JOURNAL, VOL. 21, NR. 5, PAGE(S) A690, EXPERIMENTAL BIOLOGY 2007 ANNUAL MEETING; WASHINGTON, DC, USA; APRIL 28 -MAY 02, 2007, ISSN: 0892-6638 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2006, KOLETZKO BERTHOLD: "Long-term consequences of early feeding on later obesity risk", XP002531560, Database accession no. PREV200700094766 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2007 (2007-04-01), COURVILLE AMBER B ET AL: "DHA-functional food in pregnancy decreases infant ponderal index and cord blood insulin concentration", XP002577401, Database accession no. PREV200700335301 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2008 (2008-11-01), WANG QIN ET AL: "The effect of fatty acid status of plasma phospholipids during early infancy on body mass index", XP002565704, Database accession no. PREV200900181937 *
FUDAN XUEBAO (YIXUEBAN), vol. 35, no. 6, November 2008 (2008-11-01), pages 824 - 828, ISSN: 1672-8467 *
KOLETZKO B: "PROTEIN AND ENERGY REQUIREMENTS IN INFANCY AND CHILDHOOD", ,NESTLE NUTRITION WORKSHOP SERIES PEDIATRIC PROGRAM (ISSN 0742-2806(PRINT)), 2006, BASEL (CH), pages 1 - 18, ISSN: 3-8055-8081-9(H) *
ROGGERO P ET AL: "Influence of protein and energy intakes on body composition of formula-fed preterm infants after term", JPGN JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol. 47, no. 3, September 2008 (2008-09-01), pages 375 - 378, XP009118137, ISSN: 0277-2116 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209604A (en) * 2010-11-15 2013-07-17 雀巢产品技术援助有限公司 Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2640200B1 (en) 2010-11-15 2020-12-16 Société des Produits Nestlé S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
WO2012065813A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
WO2012065810A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
WO2012065809A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2640199A1 (en) * 2010-11-15 2013-09-25 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
US11771102B2 (en) 2011-06-20 2023-10-03 H.J. Heinz Company Brands Llc Probiotic compositions and methods
EP2614724A1 (en) * 2012-01-13 2013-07-17 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring
EP2614725A1 (en) * 2012-01-13 2013-07-17 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for improving lean body mass development and formation and reducing adverse health effects later in life in offspring
WO2013106663A1 (en) * 2012-01-13 2013-07-18 Abbott Laboratories Use of specific carbohydrate systems during pregnancy for effecting the offspring
US10729733B2 (en) 2013-05-10 2020-08-04 H.J. Heinz Company Brands Llc Probiotics and methods of use
EP3073844B1 (en) 2013-11-29 2020-01-22 Société des Produits Nestlé S.A. Age-tailored nutritional compositions with a varying protein content
US12004545B2 (en) 2016-04-11 2024-06-11 Societe Des Produits Nestle S.A. Infant nutrition delivering metabolic benefits
EP3442358B1 (en) 2016-04-11 2021-02-17 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
US11388922B2 (en) 2016-04-11 2022-07-19 Societe Des Produits Nestle S.A. Infant nutrition delivering metabolic benefits

Also Published As

Publication number Publication date
CN102223812A (en) 2011-10-19
TW201026232A (en) 2010-07-16
AU2009326395A1 (en) 2010-06-17
CA2745246A1 (en) 2010-06-17
EP2373183A1 (en) 2011-10-12
US9462821B2 (en) 2016-10-11
RU2011128029A (en) 2013-01-20
RU2540541C2 (en) 2015-02-10
MX2011004921A (en) 2011-05-30
US20110244072A1 (en) 2011-10-06
AU2009326395B2 (en) 2015-02-05
BRPI0922247A2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
AU2009326395B2 (en) Modulation of infant fat mass
US9943097B2 (en) Nutritional composition
AU2006298720B2 (en) Nutritional formulation for promoting catch-up growth
AU2009268222B2 (en) Nutritional composition containing oligosaccharide mixture
CA2532472C (en) Infant or follow-on formula
US20100022451A1 (en) Use of infant formula with reduced protein content
MX2008014808A (en) Maternal supplement.
EP3073844B1 (en) Age-tailored nutritional compositions with a varying protein content
AU2019280019A1 (en) Nutritional composition for use in promoting gut and/or liver maturation and/or repair
AU2015327029B2 (en) Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
MX2008009805A (en) Nutritional composition for low birth weight infants

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146666.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756317

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12011500834

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2009756317

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009756317

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009326395

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/004921

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 3705/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009326395

Country of ref document: AU

Date of ref document: 20091123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001231

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 2745246

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13133295

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: a201107044

Country of ref document: UA

Ref document number: 2011128029

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0922247

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110607